Summary
Transdermal drug delivery systems provide controlled, continuous drug release through the skin, offering advantages including avoidance of first-pass metabolism, improved patient compliance, and steady plasma levels. Many transdermal patches rely on maintaining the API in an amorphous state within the polymer matrix to ensure rapid dissolution and consistent release kinetics over the intended delivery period (typically 24 hours).
This application note demonstrates XRPD characterization of a transdermal patch containing a dopamine-receptor agonist delivered through a polymer-based matrix. The patch was designed to release amorphous API over 24 hours. However, white deposits appeared within the borders of produced patches, indicating possible API recrystallization. DANNALAB was engaged to identify the deposits, map the crystallization pattern, and determine triggering factors.
Background & Challenge
Transdermal Patch Technology
Common transdermal products:
- Nicotine patches: Smoking cessation (NicoDerm®, Nicoderm CQ®)
- Fentanyl patches: Chronic pain management (Duragesic®)
- Estradiol patches: Hormone replacement (Climara®, Vivelle®)
- Rivastigmine patches: Alzheimer's disease (Exelon®)
- Rotigotine patches: Parkinson's disease (Neupro®)
Industry Context
API recrystallization in transdermal patches can compromise dose delivery, alter release kinetics, and potentially cause product failure. White deposits visible on patch surface indicate crystallization has occurred, but understanding the distribution, extent, and mechanism requires specialized analytical techniques beyond visual inspection.
Why API Crystallinity Matters
- Release rate: Crystalline API dissolves slower than amorphous
- Dose uniformity: Crystal formation creates concentration gradients
- Stability: Crystallization is often irreversible
- Performance: May not achieve therapeutic plasma levels
XRPD Spatial Mapping Method
Sample Information
Patch type: Polymer-based matrix delivery system
API: Dopamine-receptor agonist (novel compound)
Design specification: Amorphous API for 24-hour controlled release
Observation: White deposits appeared at patch borders
Analytical Approach
Challenge: Direct non-destructive identification of white deposits by conventional XRPD was difficult due to intensive scattering from polymer matrix.
Solution: Multi-technique approach
- Spatially resolved XRPD — Compare areas with white spots vs. clear areas
- Differentiation technique — Special method to separate API signal from polymer background
- 2D X-ray imaging — Construct crystallization area contrast maps
Methodology Reference: "Characterisation of active ingredient in formulation by differentiation of X-ray scattering patterns"; V. Kogan, DANNALAB B.V., presented at IWPCPS-14 symposium on characterisation of pharmaceutical solids.
XRPD Measurement
Instrument Parameters
- X-ray sourceCu Kα
- InstrumentLaboratory XRPD at DANNALAB
- Angular Range0-40 deg 2θ
- Special capability2D area detector for spatial mapping
Results
Phase Identification of White Deposits
Finding: Crystalline API Polymorph Identified
Using specialized differentiation technique to separate API signal from polymer matrix background, the white deposits were definitively identified as one of the crystalline polymorphs of the API. This confirmed that recrystallization from the intended amorphous state had occurred in specific regions of the patch.
Figure 1. XRPD patterns showing differentiation technique to separate crystalline API signal from polymer matrix background in transdermal patch. White deposit areas show characteristic peaks of crystalline polymorph.
Spatial Distribution Analysis
Spatially resolved XRPD was used to investigate and compare:
- Areas exhibiting white deposit formation
- Areas showing no visual irregularities
Result: Crystallization occurred predominantly at patch borders and in specific zones, not uniformly across patch surface.
2D X-Ray Imaging Results
Using 2D X-ray imaging with area detector, a contrast map was constructed showing crystallization areas across the patch surface.
Key Observations from Contrast Imaging:
- Concentric formation pattern — Crystallization exhibits concentric-type formations
- Dense crystalline cores — "Dark" areas indicating high crystalline concentration
- "Light" surrounding zones — Lower crystallinity transitional areas
- Material transport mechanism — Pattern reveals possible mechanisms of API migration and crystallization
Note: 2D measurements performed in collaboration with Dr. D. Gotz, PANalytical B.V., Almelo
Pharmaceutical Value
Value of This Investigation
What Was Achieved
- Definitive identification: Crystalline API polymorph confirmed as cause of white deposits
- Spatial mapping: Revealed distribution pattern and affected areas
- Mechanistic insights: Concentric pattern revealed material transport and crystallization mechanisms
- Process understanding: Enabled formulation of hypothesis regarding triggering factors for recrystallization in specific patch areas
Methodology Capabilities
This case demonstrates DANNALAB's capabilities for complex transdermal device analysis:
- Spatially resolved XRPD: Identify crystallization in specific patch areas
- Differentiation techniques: Separate API signal from complex polymer matrices
- 2D imaging integration: Visualize crystallization patterns across device surface
- Non-destructive analysis: Characterize intact patches without sample modification
- Mechanistic insights: Understand formation patterns and transport mechanisms
Applications
These techniques are valuable for:
- Quality investigations: Root cause analysis of crystallization issues
- Process development: Optimize manufacturing to prevent recrystallization
- Stability studies: Monitor API state changes during storage
- Method development: Develop analytical approaches for complex devices